Tharimmune, Inc. (NASDAQ:THAR) Sees Large Decrease in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 65,000 shares, a decline of 32.0% from the November 15th total of 95,600 shares. Based on an average daily trading volume, of 1,230,000 shares, the short-interest ratio is presently 0.1 days. Approximately 4.5% of the company’s stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC purchased a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune at the end of the most recent quarter. 1.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

THAR has been the topic of a number of recent analyst reports. RODMAN&RENSHAW upgraded shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw began coverage on Tharimmune in a report on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective for the company.

Tharimmune Stock Performance

THAR traded down $0.04 during trading hours on Friday, hitting $2.14. 21,274 shares of the stock were exchanged, compared to its average volume of 359,459. The stock has a 50-day simple moving average of $2.28 and a 200-day simple moving average of $2.91. Tharimmune has a 12 month low of $1.84 and a 12 month high of $8.55.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).